Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer

Previous studies have associated the overexpression of histone deacetylase 2 (HDAC2) and the presence of TP53 mutations with the progression to advanced stage drug resistant colorectal cancer (CRC). However, the mechanistic link between HDAC2 expression and the TP53 mutational status has remained un...

Full description

Bibliographic Details
Main Authors: Alzoubi, Samer, Brody, Leigh, Rahman, Sunniyat, Mahul-Mellier, Anne-Laure, Mercado, Nicolas, Ito, Kazuhiro, El-Bahrawy, Mona, Silver, Andrew, Boobis, Alan, Bell, Jimmy D., Hajji, Nabil
Format: Online
Language:English
Published: Impact Journals LLC 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190114/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190114/

Similar Items